GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Seer Inc (NAS:SEER) » Definitions » Pretax Margin %

Seer (SEER) Pretax Margin % : -682.48% (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Seer Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Seer's Pre-Tax Income for the three months ended in Mar. 2024 was $-20.68 Mil. Seer's Revenue for the three months ended in Mar. 2024 was $3.03 Mil. Therefore, Seer's pretax margin for the quarter that ended in Mar. 2024 was -682.48%.

The historical rank and industry rank for Seer's Pretax Margin % or its related term are showing as below:

SEER' s Pretax Margin % Range Over the Past 10 Years
Min: -27651.72   Med: -873.07   Max: -568.28
Current: -572.63


SEER's Pretax Margin % is ranked worse than
66.83% of 1025 companies
in the Biotechnology industry
Industry Median: -154.03 vs SEER: -572.63

Seer Pretax Margin % Historical Data

The historical data trend for Seer's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Seer Pretax Margin % Chart

Seer Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Pretax Margin %
Get a 7-Day Free Trial -27,651.72 - -1,113.06 -633.07 -568.28

Seer Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -644.41 -675.24 -552.91 -425.81 -682.48

Competitive Comparison of Seer's Pretax Margin %

For the Biotechnology subindustry, Seer's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Seer's Pretax Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Seer's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Seer's Pretax Margin % falls into.



Seer Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Seer's Pretax Margin for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-86.277/15.182
=-568.28 %

Seer's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as

Pretax Margin=Pre-Tax Income (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=-20.679/3.03
=-682.48 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Seer  (NAS:SEER) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


Seer Pretax Margin % Related Terms

Thank you for viewing the detailed overview of Seer's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Seer (SEER) Business Description

Traded in Other Exchanges
N/A
Address
3800 Bridge Parkway, Suite 102, Redwood City, CA, USA, 94065
Seer Inc is a biotechnology company. The company commercializes transformative products for researchers to unlock deep, unbiased biological information. Its product, the Proteograph Product Suite (Proteograph), will leverage its proprietary engineered nanoparticle (NP) technology to provide unbiased, deep, rapid and large-scale access across the proteome.
Executives
Elona Esq. Kogan officer: General Counsel and Secretary C/O SEER, INC., 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Omid Farokhzad director, 10 percent owner, officer: CEO and Chair of the Board C/O SEER, INC., 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Scott D Thomas officer: Chief Commercial Officer C/O SEER, INC., 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065
David R. Horn officer: Chief Financial Officer 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Omead Ostadan director, officer: President & COO C/O SEER, INC., 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Meeta Gulyani director C/O SEER, INC., 3800 BRIDGEPOINT PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Rachel E. Haurwitz director C/O CARIBOU BIOSCIENCES, INC., 2929 7TH STREET, SUITE 105, BERKELEY CA 94710
Robert Langer director 98 MONTVALE RD, NEWTON MA 02459
Maverick Ventures Investment Fund, L.p. director 300 CRESCENT COURT, SUITE 1850, DALLAS TX 75201
Maverick Capital Ventures, Llc director 300 CRESCENT COURT, SUITE 1850, DALLAS TX 75201
Maverick Advisors Fund, L.p. director 300 CRESCENT COURT, SUITE 1850, DALLAS TX 75201
David Hallal director C/O ALEXION PHARMACEUTICALS, INC, 352 KNOTTER DRIVE, CHESHIRE CT 06410
Terrance Mcguire director C/O POLARIS VENTURE PARTNERS LP, 1000 WINTER STREET, SUITE 3350, WALTHAM MA 02154
David B Singer director C/O MAVERICK CAPITAL, LTD., 101 CALIFORNIA STREET, SUITE 4015, SAN FRANCISCO CA 94111
Cathy Friedman director C/O INNOVIVA, INC., 2000 SIERRA POINT PARKWAY, SUITE 500, BRISBANE CA 94005

Seer (SEER) Headlines